Shanghai Henlius Biotech, Inc. Class H (HK:2696)
:2696
Want to see HK:2696 full AI Analyst Report?
2696 Stock Chart & Stats
HK$84.45
HK$0.05(0.21%)
At close: 4:00 PM EST
HK$84.45
HK$0.05(0.21%)
Day’s Range― - ―
52-Week RangeHK$43.80 - HK$92.00
Previous CloseN/A
Volume849.10K
Average Volume (3M)1.53M
Market Cap
HK$32.72B
Enterprise ValueHK$34.98B
Total Cash (Recent Filing)HK$972.50M
Total Debt (Recent Filing)HK$3.67B
Price to Earnings (P/E)34.8
Beta0.31
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding346,074,400
10 Day Avg. Volume1,665,497
30 Day Avg. Volume1,532,406
Financial Highlights & Ratios
PEG Ratio-17.53
Price to Book (P/B)7.08
Price to Sales (P/S)4.21
P/FCF Ratio32.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$99.12Price Target Upside17.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Profitability & MarginsHenlius sustained positive net income across 2023–2025 and maintains high gross margins (~69–74%), which supports durable product-level economics. Persistent profitability and healthy gross margins improve reinvestment capacity and resilience to pricing or reimbursement shifts over the next several quarters.
Consistent Cash GenerationMulti-year positive operating cash flow and consecutive free cash flow from 2023 onward show the company converts sales into cash. 2025 FCF covering a large portion of net income signals improving cash conversion and provides funding for R&D, manufacturing scale, or partnerships without sole reliance on external financing.
Improving Balance SheetMarked reduction in leverage versus 2022 and stronger equity positions reduce refinancing risk and increase financial flexibility. For a biotech with manufacturing and commercialization needs, lower leverage supports sustained R&D and capacity investments while lowering liquidity strain from interest and principal maturities.
Bears Say
Margin CompressionReported margin compression in 2025 and an ~8% decline in free cash flow indicate rising costs or heavier investment that compresses near-term profitability. If structural (pricing pressure, higher COGS or SG&A), this could persist and limit incremental free cash flow available for growth or debt reduction.
Residual LeverageAlthough leverage has improved, absolute debt remains material for a biotech with ongoing R&D and capex needs. Historical volatility in leverage increases sensitivity to setbacks, could constrain strategic flexibility, and raises refinancing risk if cash generation weakens or capital markets tighten.
Uneven Cash ConversionThe firm’s cash conversion has been uneven historically, including negative FCF in 2020–2022, reflecting lumpy investment cycles and commercialization ramp timing. This pattern raises the risk that future capex or development outlays could again pressure free cash flow and require external financing at inopportune times.
Shanghai Henlius Biotech, Inc. Class H News
2696 FAQ
What was Shanghai Henlius Biotech, Inc. Class H’s price range in the past 12 months?
Shanghai Henlius Biotech, Inc. Class H lowest stock price was HK$43.80 and its highest was HK$92.00 in the past 12 months.
What is Shanghai Henlius Biotech, Inc. Class H’s market cap?
Shanghai Henlius Biotech, Inc. Class H’s market cap is HK$32.72B.
When is Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Shanghai Henlius Biotech, Inc. Class H’s earnings last quarter?
Currently, no data Available
Is Shanghai Henlius Biotech, Inc. Class H overvalued?
According to Wall Street analysts Shanghai Henlius Biotech, Inc. Class H’s price is currently Undervalued.
Does Shanghai Henlius Biotech, Inc. Class H pay dividends?
Shanghai Henlius Biotech, Inc. Class H does not currently pay dividends.
What is Shanghai Henlius Biotech, Inc. Class H’s EPS estimate?
Shanghai Henlius Biotech, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Henlius Biotech, Inc. Class H have?
Shanghai Henlius Biotech, Inc. Class H has 346,074,400 shares outstanding.
What happened to Shanghai Henlius Biotech, Inc. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shanghai Henlius Biotech, Inc. Class H?
Currently, no hedge funds are holding shares in HK:2696
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Henlius Biotech, Inc. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$99.12 (17.37% Upside)
HK$99.12 (17.37% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
217.03%
12-Months-Change
Fundamentals
Return on Equity
23.99%
Trailing 12-Months
Asset Growth
22.14%
Trailing 12-Months
Company Description
Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
2696 Stock 12 Month Forecast
Average Price Target
HK$99.12
▲(17.37% Upside)
Technical Analysis
Innovent Biologics
―
3SBio
―
Wuxi Biologics (Cayman)
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Options Prices
Currently, No data available
---